|
FOCUS ON REGULATORY & COMPLIANCE |
|
|
|
By Erin Harris, Editor-In-Chief, Cell & Gene | This session recap from Advanced Therapies USA Congress 2026 explains why the CGT industry cannot evaluate success through clinical data alone. | |
|
|
|
| An Overview Of 2026 Life Sciences Industry Trends | White Paper | MasterControl, Inc. | Explore the paradigm shift reshaping life sciences, how connected data streams across the product lifecycle drive predictive compliance and operational excellence. |
|
|
|
|
|
|
|
| Optimizing Bioprocess Design And Workflow Orchestration | White Paper | Revvity Signals Software, Inc. | Disconnected systems can slow development by making data harder to coordinate. Discover how workflow orchestration and structured experimental design can help labs reduce friction and improve efficiency. |
|
|
|
|
|
|
| How Phase I Trial Ethics Are Changing For Sponsors | Article | BRANY | As early efficacy becomes possible in Phase I studies, hope for benefit must be weighed against limited knowledge, reshaping consent language, risk-benefit review, and protocol design for sponsors and IRBs. |
|
|
| Advancing The Human Liver-Chip Toward FDA Qualification | Webinar | Emulate | Investigate how human-relevant liver models can improve DILI risk assessment and support stronger development decisions while advancing toward regulatory qualification and scaling into automated studies. |
|
|
REGULATORY & COMPLIANCE SOLUTIONS |
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|